AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 30770221
Drug: Booster dose
RxNorm normalized name: SARS-COV-2 (COVID-19) Vaccine, mRNA (Moderna) 50 MCG/0.5 ML Intramuscular Suspension [MODERNA COVID-19 VACCINE BOOSTER DOSE]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Booster dose of MenB-FHbp vaccine administered 48 months after primary vaccination
Trial: 30770310
Drug: avalglucosidase alfa
RxNorm normalized name: Avalglucosidase alfa
DrugBank: Avalglucosidase alfa (DB16099)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: avalglucosidase alfa 5 mg/kg
Trial: 30770310
Drug: avalglucosidase alfa
RxNorm normalized name: Avalglucosidase alfa
DrugBank: Avalglucosidase alfa (DB16099)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: avalglucosidase alfa 10 mg/kg
Trial: 30770310
Drug: avalglucosidase alfa
RxNorm normalized name: Avalglucosidase alfa
DrugBank: Avalglucosidase alfa (DB16099)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: avalglucosidase alfa 20 mg/kg
Trial: 30770348
Drug: Navoximod (GDC-0919)
RxNorm normalized name: calcium carbonate
DrugBank: Navoximod (DB15439)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Navoximod (GDC-0919) in combination with PD-L1 inhibitor Atezolizumab
Trial: 30770534
Drug: Wild-type influenza
RxNorm normalized name: Influenza A virus A/Brisbane/10/2010 (H1N1) wild type
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wild-type influenza A(H3N2)2011 virus (any dose)
Trial: 30771200
Drug: DSF/Cu (disulfiram
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DSF/Cu (disulfiram and copper) plus standard monthly temozolomide (TMZ) 80 mg PO TID and Cu 1.5 mg PO TID
Trial: 30772821
Drug: Cooled radiofrequency
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cooled radiofrequency ablation (CRFA) after intra-articular steroid injection (IAS)
Trial: 30772864
Drug: Vaccination against
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccination against five vaccine targets (pneumococcus, hepatitis B virus, etc.), specific details on dosage and duration not available.
Trial: 30772905
Drug: Daily wild
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily wild blueberry consumption for 1 month
Trial: 30772905
Drug: Injection of
RxNorm normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection of anthocyanin metabolites in mice
Trial: 30772905
Drug: Daily wild
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily wild blueberry consumption
Trial: 30773463
Drug: BCL-2 inhibitor
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: BCL-2 inhibitor ABT-199
Trial: 30774399
Drug: Initial antibiotic
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Initial antibiotic therapy (IAT; antibiotics administered ≤48 hours post-initiation of antibiotic therapy)
Trial: 30774635
Drug: Liposome-based vaccines
RxNorm normalized name: covid-19, RNA-based vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liposome-based vaccines
Trial: 30776363
Drug: Injection of
RxNorm normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection of 1.5 mg of paclitaxel
Trial: 30776452
Drug: Pravastatin 40
RxNorm normalized name: pravastatin 40 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin 40 mg/d for 12 months
Trial: 30777022
Drug: 22 weekly
RxNorm normalized name: elagolix
DrugBank: Elagolix (DB11979)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 22 weekly group sessions called School of Health for Older People
Trial: 30777049
Drug: Patient education
RxNorm normalized name: DIABETES PATIENT EDUCATION PACK
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient education and exercise therapy (group-based program with 2 sessions of education and 8 weeks of supervised exercises)
Trial: 30777875
Drug: Alisertib (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alisertib (80 mg/m2)
Trial: 30778280
Drug: rTMS combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rTMS combined with Intensive Language-Action Therapy
Trial: 30778345
Drug: Subcutaneous Immunoglobulin
RxNorm normalized name: immunoglobulin A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous Immunoglobulin 16.5% (Octanorm [Cutaquig®])
Trial: 30778520
Drug: Weekly paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Weekly paclitaxel for 13 weeks combined with trastuzumab-pertuzumab in molecular non-responders
Trial: 30780166
Drug: Adrenaline infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adrenaline infusion (0.01, 0.05, 0.10 and 0.15 µg/kg/min; 15 minutes at each step)
Trial: 30782698
Drug: Liposomal lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Liposomal lidocaine 4% cream (topical anaesthetic)
Trial: 30782749
Drug: Weekly emails
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly emails and monthly phone calls for 3 months
Trial: 30782924
Drug: Hospital treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hospital treatment for non-complex fractures or dislocations
Trial: 30782999
Drug: Levofloxacin (750-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levofloxacin (750- to 1,000-mg once-daily dosing)
Trial: 30783204
Drug: Eribulin mesilate
RxNorm normalized name: Eribulin mesilate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eribulin mesilate (1.6 mg/m²) in combination with capecitabine (1000 mg/m² twice daily)
Trial: 30785829
Drug: Nivolumab plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab plus low-dose ipilimumab (nivolumab 3 mg/kg every 2 weeks plus ipilimumab 1 mg/kg every 6 weeks)
Trial: 30786188
Drug: Sacituzumab govitecan-hziy
RxNorm normalized name: sacituzumab govitecan-hziy
DrugBank: Sacituzumab govitecan (DB12893)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Sacituzumab govitecan-hziy (10 mg/kg) administered intravenously on days 1 and 8 of each 21-day cycle until disease progression or unacceptable toxic effects.
Trial: 30787085
Drug: Patient Information
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient Information Leaflets (PILs) given by physicians along with an oral explanation.
Trial: 30787176
Drug: TAS0728, a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAS0728, a covalent-binding HER2-selective kinase inhibitor
Trial: 30787641
Drug: Vitamin D3
RxNorm normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D3 (50,000 IU weekly)
Trial: 30787641
Drug: Omega-3 fatty
RxNorm normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega-3 fatty acids (300 mg daily)
Trial: 30787641
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Vitamin D3 and Omega-3 fatty acids
Trial: 30788134
Drug: Pharmacist-administered HIV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacist-administered HIV point-of-care testing (POCT) with pre/post-test counseling and linkage to care plans
Trial: 30788134
Drug: Pharmacist-administered HIV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacist-administered HIV point-of-care testing (POCT)
Trial: 30789827
Drug: 12-week intensive
RxNorm normalized name: risedronate
DrugBank: Risedronic acid (DB00884)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 12-week intensive outpatient rehabilitation including memantine and morphine treatment, psychological and physiotherapeutic intervention
Trial: 30790469
Drug: Palliative gastric
RxNorm normalized name: gastric mucins
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Palliative gastric radiotherapy (36 Gy in 12 daily fractions)
Trial: 30792190
Drug: Clarithromycin 500
RxNorm normalized name: clarithromycin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clarithromycin 500 mg orally twice daily, pomalidomide 4 mg orally on days 1 to 21, and dexamethasone 40 mg orally on days 1, 8, 15, and 22 of a 28-day cycle
Trial: 30793701
Drug: Drugs associated
RxNorm normalized name: HEPATITIS ASSOCIATED ANTIBODY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drugs associated with drug-induced lupus (DIL)
Trial: 30794033
Drug: Induced subgroups
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induced subgroups from empirical data on treatment effectiveness
Trial: 30795996
Drug: Daratumumab (16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daratumumab (16 mg/kg; administered intravenously weekly for 2 cycles, every 2 weeks for 4 cycles, and every 4 weeks thereafter)
Trial: 30796032
Drug: MTI-31 (LXI-15029),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MTI-31 (LXI-15029), a novel mTORC1/mTORC2 inhibitor
Trial: 30796035
Drug: ADI-PEG20 (36
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ADI-PEG20 (36 mg/m weekly) with pemetrexed and cisplatin (ADIPEMCIS)
Trial: 30796155
Drug: Genexol-PM (230
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Genexol-PM (230 mg/m2) plus cisplatin
Trial: 30796821
Drug: Overall treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall treatment (pertuzumab, trastuzumab, and taxane)
Trial: 30796821
Drug: Docetaxel-containing therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Docetaxel-containing therapy
Trial: 30796821
Drug: Paclitaxel-containing therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paclitaxel-containing therapy
Trial: 30797139
Drug: Bendamustine and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bendamustine and rituximab (BR) as first-line treatment
Trial: 30797575
Drug: Opioid prescription
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Opioid prescription and pain management
Trial: 30797634
Drug: ACE527 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACE527 vaccine with dmLT adjuvant
Trial: 30797634
Drug: ACE527 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACE527 vaccine without adjuvant
Trial: 30797636
Drug: Pneumococcal polysaccharide-based
RxNorm normalized name: PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 8
DrugBank: Streptococcus pneumoniae type 8 capsular polysaccharide antigen (DB10326)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pneumococcal polysaccharide-based vaccines (PPV and/or PCV/PPV)
Trial: 30800421
Drug: ABX464 150-mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABX464 150-mg
Trial: 30800421
Drug: ABX464 50-mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABX464 50-mg
Trial: 30800562
Drug: Ipragliflozin 50
RxNorm normalized name: BEXAGLIFLOZIN
DrugBank: Bexagliflozin (DB12236)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ipragliflozin 50 mg once-daily
Trial: 30800562
Drug: Ipragliflozin with
RxNorm normalized name: bexagliflozin
DrugBank: Bexagliflozin (DB12236)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ipragliflozin with DPP-4 inhibitor
Trial: 30801647
Drug: Tomato-soy juice
RxNorm normalized name: tomato juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tomato-soy juice (0, 1, or 2 cans/day; 163 mL/can; 20.6 mg lycopene, 1.2 mg β-carotene/can) for 24 ± 0.7 days
Trial: 30801984
Drug: Total Daily
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total Daily Energy Expenditure (TDEE) in WLM
Trial: 30801989
Drug: Daily dietary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily dietary self-monitoring using a Web-based dietary analysis program
Trial: 30802998
Drug: VY-AADC01 (8.3 × 10^10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VY-AADC01 (8.3 × 10^10 vg/mL) administered bilaterally with gadoteridol using MRI guidance
Trial: 30803705
Drug: Miransertib at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Miransertib at a dose of 5 mg/m
Trial: 30803990
Drug: Parsaclisib monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parsaclisib monotherapy (5-45 mg once daily)
Trial: 30803997
Drug: Non-drug interventions
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-drug interventions for perinatal depression
Trial: 30803997
Drug: Personalized treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Personalized treatment approaches
Trial: 30803997
Drug: Novel treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Novel treatments under investigation
Trial: 30804020
Drug: Chimeric HER-2
RxNorm normalized name: HER-2/neu inhibitor
DrugBank: RGG0853 (DB18669)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chimeric HER-2 B-cell peptide vaccines emulsified in Montanide ISA 720VG and Nor-MDP adjuvant, administered as three inoculations every 3 weeks.
Trial: 30805946
Drug: Methadone (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methadone (single oral dose)
Trial: 30805946
Drug: Simplified dosing
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simplified dosing strategy (model-based simulations)
Trial: 30808583
Drug: Afatinib (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Afatinib (40 mg/d) with Pembrolizumab (200 mg every 3 weeks)
Trial: 30809591
Drug: Intrathecal tetanus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal tetanus antitoxin and human intramuscular treatment
Trial: 30809591
Drug: Intrathecal tetanus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal tetanus antitoxin and equine intramuscular treatment
Trial: 30809591
Drug: Sham procedure
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Sham procedure and human intramuscular treatment
Trial: 30809591
Drug: Sham procedure
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Sham procedure and equine intramuscular treatment
Trial: 30810343
Drug: Pre-treatment PET
RxNorm normalized name: Pet-ema
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-treatment PET parameters (FDG-PET/CT)
Trial: 30810343
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of HPV with PET parameters (MTV, TLG, ZMP)
Trial: 30810343
Drug: PET 2
RxNorm normalized name: benzocain-camphor-allatoin-pet 20 %-3 %-1 %-64.9 % TOPICAL OINTMENT (GRAM)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PET 2 weeks into treatment
Trial: 30810343
Drug: Pre-treatment PET
RxNorm normalized name: Pet-ema
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-treatment PET parameters
Trial: 30810343
Drug: Changes in
RxNorm normalized name: guaifenesin / hydrocodone bitartrate Oral Solution [Canges XP]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Changes in PET parameters from pre- to mid-treatment
Trial: 30811142
Drug: Tavaborole 5%
RxNorm normalized name: TAVABOROLE 5% SOLN,TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tavaborole 5% topical solution applied once daily to all affected toenails for 48 weeks
Trial: 30811142
Drug: Tavaborole 5%
RxNorm normalized name: TAVABOROLE 5% SOLN,TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tavaborole 5% topical solution applied for the first 28 days to all 10 toenails and ≤2 mm of surrounding skin in a maximal-use subgroup (aged 12 to <17 years)
Trial: 30811285
Drug: Hu5F9-G4 (5F9)
RxNorm normalized name: human-bovine reassortant rotavirus strain G1 vaccine / human-bovine reassortant rotavirus strain G2 vaccine / human-bovine reassortant rotavirus strain G3 vaccine / human-bovine reassortant rotavirus strain G4 vaccine / human-bovine reassortant rotavirus strain P1A[8] vaccine Oral Suspension [RotaTeq]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hu5F9-G4 (5F9) antibody at a priming dose of 1 mg/kg followed by maintenance doses of 3 to 45 mg/kg weekly
Trial: 30811537
Drug: Asfotase alfa
RxNorm normalized name: Asfotase alfa
DrugBank: Asfotase alfa (DB09105)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Asfotase alfa 2 mg/kg three times/week or 1 mg/kg six times/week subcutaneously
Trial: 30814321
Drug: Candesartan (16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Candesartan (16 mg) plus hydrochlorothiazide (12.5 mg)
Trial: 30814321
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (Candesartan plus Hydrochlorothiazide and Rosuvastatin)
Trial: 30815467
Drug: Blood and
RxNorm normalized name: BLOOD AND RELATED PRODUCTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blood and sputum sampling monthly and at exacerbation to detect respiratory infections and eosinophilic inflammation
Trial: 30815468
Drug: Inhaled corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled corticosteroids and one or more bronchodilators prior to study entry
Trial: 30816809
Drug: Real-world therapies
RxNorm normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Real-world therapies chosen for multiple myeloma patients
Trial: 30819210
Drug: Sotagliflozin (as
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sotagliflozin (as monotherapy or add-on therapy)
Trial: 30819210
Drug: Sotagliflozin (in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sotagliflozin (in adults with T1D treated with continuous subcutaneous insulin infusion or multiple daily insulin injections)
Trial: 30819913
Drug: Platelet transfusions
RxNorm normalized name: platelet glycoprotein VI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platelet transfusions at a threshold platelet count of 50x10^9/L
Trial: 30821848
Drug: ipilimumab treatment
RxNorm normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: ipilimumab treatment
Trial: 30822272
Drug: sitagliptin 100
RxNorm normalized name: SITagliptin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sitagliptin 100 mg, once daily
Trial: 30822272
Drug: vildagliptin 50
RxNorm normalized name: vildagliptin 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: vildagliptin 50 mg, twice daily
Trial: 30822272
Drug: saxagliptin 5
RxNorm normalized name: sAXagliptin 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: saxagliptin 5 mg, once daily
Trial: 30822389
Drug: Lumbar stabilization
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lumbar stabilization exercise program (twice a week for 8 weeks)
Trial: 30825104
Drug: Pexidartinib 600
RxNorm normalized name: PEXIDARTINIB
DrugBank: Pexidartinib (DB12978)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pexidartinib 600 mg/d
Trial: 30825104
Drug: Pexidartinib 1000
RxNorm normalized name: PEXIDARTINIB
DrugBank: Pexidartinib (DB12978)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pexidartinib 1000 mg/d for 2 weeks, then 800 mg/d thereafter
Trial: 30825970
Drug: Concurrent SBRT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent SBRT (40 Gy) and nelfinavir (1250 mg BID for 5 weeks)
Trial: 30826528
Drug: Admission cTnI
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Admission cTnI > 0.46 ng/mL with STEMI present in ECG
Trial: 30832606
Drug: Pembrolizumab 10
RxNorm normalized name: pembrolizumab 100 MG in 4 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab 10 mg/kg administered every 2 weeks up to 24 months or until confirmed progression or intolerable toxicity
Trial: 30832636
Drug: Persona Knee
RxNorm normalized name: Bos taurus knee joint preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Persona Knee Implant System
Trial: 30832732
Drug: α-PD-1 therapy
RxNorm normalized name: Recombinant pd-1 mab cs1003
DrugBank: Nofazinlimab (DB18852)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: α-PD-1 therapy
Trial: 30832732
Drug: α-TGFβ monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: α-TGFβ monotherapy
Trial: 30832732
Drug: α-PD-1 and
RxNorm normalized name: Recombinant pd-1 mab cs1003
DrugBank: Nofazinlimab (DB18852)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: α-PD-1 and α-TGFβ combinatorial therapy
Trial: 30832732
Drug: α-TGFβ antibody
RxNorm normalized name: digoxin antibodies Fab fragments
FDA approved: no
EMA approved: no
PMDA approved: no
Description: α-TGFβ antibody administration
Trial: 30833313
Drug: Biomarkers of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biomarkers of interest focusing on metabolism (lipids, amino acids) and inflammation (adipokines, cytokines, and chemokines).
Trial: 30833442
Drug: Carboplatin treatment
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin treatment with hypersensitivity reaction management
Trial: 30833489
Drug: Merestinib (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Merestinib (120 mg once daily)
Trial: 30834280
Drug: Nutritional supplement
RxNorm normalized name: Nutritional supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutritional supplement (Progen) containing hydrolyzed collagen peptides, plasma proteins, hyaluronic acid-chondroitin sulfate complex, and vitamin C
Trial: 30834940
Drug: sunitinib 37.5
RxNorm normalized name: sunitinib 37.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sunitinib 37.5 mg/day on a continuous daily dosing schedule